A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg D-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking D-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.
Goodall
E
E
Academic Unit of Human Psychopharmacology, Medical College, St Bartholomew's Hospital.
Oxtoby
C
C
Richards
R
R
Watkinson
G
G
Brown
D
D
Silverstone
T
T
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D015431:Weight Loss / Q000187:drug effects
D014150:Antipsychotic Agents; D005277:Fenfluramine